United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Technology News Does BioHive-2 redefine capital efficiency for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX)? Can BioHive-2 accelerate Recursion Pharmaceuticals’ pipeline and justify its AI infrastructure bet? Explore the strategic stakes for NASDAQ: RXRX. bySoujanya RaviFebruary 25, 2026